Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xentuzumab and Abemaciclib in Solid Tumours and Breast Cancer
NCT03099174Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2017
- Primary completion
- May 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 1, open-label trial of xentuzumab in solid tumor, breast cancer and non-small cell lung cancer (NSCLC) (8 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose Limiting Toxicities at 28 days and 3 more. Started May 2017; status: completed.
02
Drugs
xentuzumab
03
Conditions
solid tumorbreast cancernon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03099174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03099174.